Molecular Mechanism of Cannabinoids in Cancer Progression.
angiogenesis
cancer
cannabinoids
cell death
migration
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
01 Apr 2021
01 Apr 2021
Historique:
received:
09
03
2021
revised:
28
03
2021
accepted:
28
03
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
18
5
2021
Statut:
epublish
Résumé
Cannabinoids are a family of heterogeneous compounds that mostly interact with receptors eliciting several physiological effects both in the central and peripheral nervous systems and in peripheral organs. They exert anticancer action by modulating signaling pathways involved in cancer progression; furthermore, the effects induced by their use depend on both the type of tumor and their action on the components of the endocannabinoid system. This review will explore the mechanism of action of the cannabinoids in signaling pathways involved in cancer proliferation, neovascularisation, migration, invasion, metastasis, and tumor angiogenesis.
Identifiants
pubmed: 33916164
pii: ijms22073680
doi: 10.3390/ijms22073680
pmc: PMC8037087
pii:
doi:
Substances chimiques
Cannabinoids
0
Endocannabinoids
0
Ligands
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Endocrinology. 2010 Mar;151(3):921-8
pubmed: 20133454
Biochem Pharmacol. 2018 Nov;157:266-274
pubmed: 30195736
Neuropharmacology. 2008 Jan;54(1):235-43
pubmed: 17675107
PLoS One. 2016 Dec 9;11(12):e0167848
pubmed: 27936102
Oncogene. 2008 Jan 10;27(3):339-46
pubmed: 17621270
Methods Mol Med. 2001;46:107-29
pubmed: 21340916
Int J Mol Sci. 2020 Nov 13;21(22):
pubmed: 33202711
Am J Obstet Gynecol. 2014 Sep;211(3):234.e1-6
pubmed: 24721263
Cancer Lett. 2011 Aug 1;307(1):6-17
pubmed: 21543155
J Cell Physiol. 2012 Jan;227(1):250-8
pubmed: 21412772
Cell Death Differ. 2003 Sep;10(9):946-55
pubmed: 12934069
Molecules. 2020 Oct 14;25(20):
pubmed: 33066359
Expert Rev Clin Pharmacol. 2017 Apr;10(4):443-455
pubmed: 28276775
Prostate. 2019 Feb;79(2):151-159
pubmed: 30242861
Cancers (Basel). 2020 Oct 30;12(11):
pubmed: 33143283
FEBS Lett. 2005 Nov 21;579(28):6343-9
pubmed: 16263116
Onco Targets Ther. 2016 Jul 18;9:4323-36
pubmed: 27486335
Pharmacol Ther. 2017 Jul;175:133-150
pubmed: 28232276
Pharmacol Biochem Behav. 2010 Jun;95(4):375-82
pubmed: 20347862
Pharm Res. 2009 Feb;26(2):346-55
pubmed: 19015962
J Cancer Res Clin Oncol. 2018 Jan;144(1):39-52
pubmed: 28993942
PLoS One. 2011;6(10):e26823
pubmed: 22046372
Cancer Res. 2008 Aug 1;68(15):6468-76
pubmed: 18676872
Evid Based Complement Alternat Med. 2020 Jul 20;2020:2371527
pubmed: 32765628
Int J Oncol. 2006 Jun;28(6):1327-35
pubmed: 16685433
Int J Mol Sci. 2020 Jan 23;21(3):
pubmed: 31979368
Leuk Res. 2020 Aug;95:106389
pubmed: 32540572
Cancer Res. 2004 Dec 15;64(24):8826-30
pubmed: 15604240
Br J Anaesth. 2010 May;104(5):596-602
pubmed: 20354008
Prostaglandins Other Lipid Mediat. 2011 Feb;94(1-2):34-43
pubmed: 21167293
Oncotarget. 2016 Nov 22;7(47):77543-77557
pubmed: 27769052
Mol Carcinog. 2016 Nov;55(11):1807-1821
pubmed: 26513129
Anticancer Res. 2015 May;35(5):2657-61
pubmed: 25964542
Int J Cancer. 2018 Jan 1;142(1):176-190
pubmed: 28884474
Int J Mol Sci. 2018 Mar 13;19(3):
pubmed: 29533978
Int J Mol Sci. 2014 May 08;15(5):8063-74
pubmed: 24815068
Oncol Rep. 2007 Apr;17(4):813-6
pubmed: 17342320
Oncotarget. 2017 May 2;8(18):29668-29678
pubmed: 27213582
Iran J Pharm Res. 2017 Fall;16(4):1479-1486
pubmed: 29552056
Tumour Biol. 2016 Oct 18;:
pubmed: 27757850
Life Sci. 2015 Oct 1;138:41-51
pubmed: 25445433
Toxicol Lett. 2012 Nov 15;214(3):314-9
pubmed: 22963825
Cancer Manag Res. 2013 Aug 30;5:301-13
pubmed: 24039449
Hum Reprod Update. 2015 Jul-Aug;21(4):517-35
pubmed: 25958409
J Clin Endocrinol Metab. 2001 Jun;86(6):2687-96
pubmed: 11397872
Cancers (Basel). 2020 Jul 21;12(7):
pubmed: 32708138
Biochem J. 2000 Nov 1;351 Pt 3:817-24
pubmed: 11042139
EBioMedicine. 2019 Jun;44:452-466
pubmed: 31151929
Mol Med Rep. 2015 Dec;12(6):7963-70
pubmed: 26500101
Chem Biol. 2011 Jul 29;18(7):846-56
pubmed: 21802006
Cell. 2010 Jan 8;140(1):49-61
pubmed: 20079333
Int J Mol Sci. 2020 Jul 17;21(14):
pubmed: 32709050
Cancers (Basel). 2019 Dec 31;12(1):
pubmed: 31906201
Int J Mol Sci. 2019 Apr 03;20(7):
pubmed: 30987191
Breast Cancer (Dove Med Press). 2016 Apr 15;8:59-71
pubmed: 27186076
Pharmacol Res. 2017 May;119:227-236
pubmed: 28193521
FASEB J. 2004 Oct;18(13):1606-8
pubmed: 15289448
Br J Pharmacol. 2007 Mar;150(5):613-23
pubmed: 17245363
Funct Neurol. 2001;16(4 Suppl):53-60
pubmed: 11996531
Mol Pharmacol. 2006 Jul;70(1):51-9
pubmed: 16571653
Cell Death Dis. 2011 Apr 28;2:e152
pubmed: 21525939
Cell Physiol Biochem. 2016;39(6):2149-2157
pubmed: 27802436
Mol Pharmacol. 1995 Sep;48(3):443-50
pubmed: 7565624
Int J Cancer. 2008 Sep 15;123(6):1318-26
pubmed: 18566995
Front Oncol. 2019 Dec 19;9:1363
pubmed: 31921630
Mol Cancer. 2010 Jul 22;9:196
pubmed: 20649976
Biomolecules. 2019 Jul 25;9(8):
pubmed: 31349651
FASEB J. 2012 Apr;26(4):1535-48
pubmed: 22198381
Br J Pharmacol. 2019 May;176(10):1361-1369
pubmed: 29797438
Cancer Res. 2006 Jul 1;66(13):6615-21
pubmed: 16818634
J Natl Cancer Inst. 2008 Jan 2;100(1):59-69
pubmed: 18159069
J Leukoc Biol. 2016 Apr;99(4):531-40
pubmed: 26467187
Cell Death Dis. 2019 Nov 7;10(11):846
pubmed: 31699976
Mol Med Rep. 2016 Mar;13(3):2850-6
pubmed: 26847687
Gastroenterology. 2003 Sep;125(3):677-87
pubmed: 12949714
J Neurochem. 2005 Apr;93(2):299-309
pubmed: 15816853
Toxicol In Vitro. 2015 Oct;29(7):1941-51
pubmed: 26255146
Nat Rev Cancer. 2012 May 04;12(6):436-44
pubmed: 22555283
Bratisl Lek Listy. 2020;121(1):79-95
pubmed: 31950844
Oncotarget. 2016 Mar 22;7(12):15047-64
pubmed: 26930716
Adv Exp Med Biol. 2020;1202:223-241
pubmed: 32034716
Eur J Cancer. 2012 Nov;48(16):3112-22
pubmed: 22425263
PLoS One. 2020 Feb 12;15(2):e0228909
pubmed: 32049991
Mol Cancer Ther. 2009 Nov;8(11):3117-29
pubmed: 19887554
J Neurochem. 2012 Mar;120(5):842-9
pubmed: 22176552
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8375-80
pubmed: 9653194
Br J Pharmacol. 2010 Aug;160(7):1583-94
pubmed: 20649563
Br J Cancer. 2009 Sep 15;101(6):940-50
pubmed: 19690545
Pharmacol Res. 2017 Jan;115:233-241
pubmed: 27832960
Exp Cell Res. 2006 Feb 15;312(4):363-73
pubmed: 16343481
Arch Toxicol. 2013 Nov;87(11):1939-1951
pubmed: 23552853
Int J Cancer. 2008 Feb 15;122(4):742-50
pubmed: 17943729
Oncotarget. 2014 May 15;5(9):2475-86
pubmed: 24811863
Int J Cancer. 2009 Sep 1;125(5):996-1003
pubmed: 19479993
Mol Cancer Ther. 2011 Jul;10(7):1161-72
pubmed: 21566064
BMC Cancer. 2012 Mar 19;12:92
pubmed: 22429826
Chem Phys Lipids. 2002 Dec 31;121(1-2):111-34
pubmed: 12505695
J Hematol Oncol. 2016 Nov 25;9(1):127
pubmed: 27884159
Oncol Rep. 2015 Jul;34(1):447-54
pubmed: 25975960
Sci Rep. 2016 Oct 21;6:35784
pubmed: 27767105
J Pain. 2012 May;13(5):438-49
pubmed: 22483680
Cancer Res. 2005 Mar 1;65(5):1635-41
pubmed: 15753356
Nat Commun. 2020 Jun 12;11(1):2978
pubmed: 32532977
Br J Pharmacol. 2011 Aug;163(7):1447-63
pubmed: 21410463
Br J Pharmacol. 2016 Jan;173(1):142-54
pubmed: 26436760
Int J Mol Sci. 2020 Jan 25;21(3):
pubmed: 31991773
Cancer Prev Res (Phila). 2011 Jan;4(1):65-75
pubmed: 21097714
Front Pharmacol. 2019 May 31;10:621
pubmed: 31214034
Int J Mol Sci. 2020 Oct 17;21(20):
pubmed: 33080916
Bioorg Med Chem Lett. 2010 Oct 15;20(20):5959-68
pubmed: 20817522
Pharmaceuticals (Basel). 2020 Jul 30;13(8):
pubmed: 32751761
Mol Cancer Ther. 2017 Jan;16(1):57-67
pubmed: 27760835
Trends Mol Med. 2020 Mar;26(3):263-272
pubmed: 31822395
Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):1-15
pubmed: 19285257
Int J Mol Sci. 2019 Oct 22;20(20):
pubmed: 31652569
Br J Pharmacol. 2018 Jul;175(13):2566-2580
pubmed: 29663308
Lab Invest. 2011 Jul;91(7):1007-17
pubmed: 21464819
Mol Carcinog. 2016 Dec;55(12):2063-2076
pubmed: 26741322